MedTrace Logo

Safety of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy Volunteer

NCT07532135 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-04-23

No results posted yet for this study

Summary

Volunteers were divided into 2 groups: mulberry leaf extract capsule (DNJ 12mg) group and placebo group. They took the sample 3 times/day for 8 weeks. Complete blood count, Blood urea nitrogen (BUN), Creatinine, Aspartate transaminase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Fasting plasma glucose, HbA1c, and adverse effects were evaluated before and after 4 and 8 weeks.

Conditions

  • Healthy Volunteers
  • Non Diabetic Hyperglycemia

Interventions

COMBINATION_PRODUCT

Mulberry Leaf Extract

They took the Mulberry leaf extract capsule (DNJ 12mg) 3 times/day for 8 weeks.

OTHER

Placebo

They took the sample 3 times/day for 8 weeks.

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-09-01
Completion
2026-09-24

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07532135 on ClinicalTrials.gov